Drugs affecting the respiratory system Quizlet

Option D: II and III are correct, as chronic bronchitis is characterized by an increased number of mucous glands and goblet cells, leading to excessive mucus production, and by edema and inflammation of the bronchioles, which contribute to airway obstruction and respiratory symptoms. These features are key in the pathophysiology of chronic bronchitis.

Option A: The destruction of central and peripheral portions of the acinus pertains to emphysema, not chronic bronchitis. Chronic bronchitis primarily involves inflammation and mucus hypersecretion rather than acinar destruction.

Option B: An increased number of mucous glands and goblet cells is a hallmark of chronic bronchitis, making this option partially correct but not sufficient alone to define the condition without considering the accompanying inflammation.

Option C: Edema and inflammation of the bronchioles are indeed characteristics of chronic bronchitis, but this option alone does not encompass the full definition of the disease without the context of mucus hypersecretion.

Takeaways: Chronic bronchitis is defined by increased mucous gland activity and inflammation of the airways, leading to significant respiratory issues, which requires patient education on managing chronic bronchitis symptoms for effective treatment and care.

Option B: Dextromethorphan is an effective non-sedating cough suppressant that works on the central nervous system to reduce the cough reflex without causing sedation or other unwanted effects, making it suitable for managing cough in asthma patients awaiting the full effect of other medications.

Option A: Codeine is an opioid that can suppress cough but often causes sedation and has a risk of dependency, making it unsuitable for this patient scenario.

Option C: Diphenhydramine is an antihistamine that can cause sedation and is not primarily indicated for cough suppression, thus not ideal for this situation.

Option D: Pholcodine is a cough suppressant but may not be as effective or well-tolerated as dextromethorphan, particularly in pediatric patients.

Takeaways: Dextromethorphan serves as a non-sedating cough suppressant suitable for asthma management, especially when other medications are being initiated; understanding its role is crucial for effective patient care in respiratory conditions requiring cough management strategies.

Option D: Stop the treatment and notify the physician. This action is crucial as a significant increase in heart rate following the administration of an adrenergic aerosol bronchodilator indicates potential cardiovascular stress or adverse effects. Immediate cessation of the treatment allows for patient safety and assessment by a physician, who may need to adjust the treatment plan or monitor for further complications.

Option A: Use half of the standard dosage next time. Reducing the dosage in future treatments does not address the immediate concern of the patient's elevated heart rate and could lead to inadequate bronchodilation if the same dosage is required for therapeutic effect.

Option B: Add more diluent to the nebulizer chamber. This action does not resolve the acute issue of the patient's increased heart rate and may dilute the medication's effectiveness, potentially worsening the patient's respiratory condition.

Option C: Temporarily stop the treatment until the patient's heart rate decreases. While this option considers patient safety, it lacks the necessary action of notifying a physician, which is essential for proper management of the situation and ensuring comprehensive care.

Takeaways: Monitoring vital signs during bronchodilator therapy is essential, as significant changes, such as increased heart rate, require immediate clinical intervention and physician notification to ensure patient safety and effective management.

Option C: Salbutamol inhalation is the most useful treatment for an acute attack of bronchial asthma due to its rapid bronchodilator effect. Salbutamol, a short-acting beta-2 adrenergic agonist, quickly relaxes bronchial smooth muscle, providing immediate relief from bronchospasm and improving airflow. This makes it the first-line choice during acute asthma exacerbations.

Option A: Beclomethasone aerosol is a corticosteroid used for long-term management of asthma, not for acute attacks. It works by reducing inflammation but does not provide immediate relief during an acute episode.

Option B: Methacholine is a bronchoconstrictor used primarily for diagnostic purposes in asthma testing, not for treatment of acute asthma attacks. It induces bronchospasm rather than alleviating it.

Option D: Chlorpheniramine is an antihistamine that is not effective for treating bronchial asthma. It does not address bronchospasm and is primarily used for allergic reactions and symptoms.

Takeaways: Salbutamol inhalation is essential for managing acute asthma attacks due to its rapid bronchodilator effects, while other options like beclomethasone and chlorpheniramine do not provide immediate relief. Understanding the role of bronchodilators in asthma management is crucial for effective treatment, as highlighted in this resource on asthma management.

Option C: Change to hypertonic saline. Hypertonic saline (3% or higher) can help to draw water into the airways, thereby increasing mucus production and facilitating sputum expectoration. This is particularly beneficial when a patient is unable to produce an adequate sputum sample, as it enhances airway hydration and promotes clearance of secretions.

Option A: Initiate chest physiotherapy. While chest physiotherapy can aid in mucus clearance, it does not directly address the need for increased sputum production in this scenario. The immediate goal is to enhance sputum volume, which hypertonic saline achieves more effectively.

Option B: Administer the aerosol continuously. Continuous aerosol therapy with 0.9% saline may not provide the necessary osmotic effect to increase sputum production. Hypertonic saline is more effective in stimulating mucus secretion compared to isotonic saline.

Option D: Perform nasotracheal suctioning. This intervention is invasive and may not be necessary if the goal is to enhance sputum production. It does not address the underlying issue of insufficient mucus production and could cause discomfort or complications.

Takeaways: Hypertonic saline enhances airway hydration and mucus production, making it a preferred choice for patients unable to produce adequate sputum samples; this requires appropriate assessment and intervention for airway management to ensure effective treatment.

Option C: 2-Thiazolyl ethylamine is a selective H3 receptor agonist, which plays a crucial role in modulating neurotransmitter release in the central nervous system. Its selectivity for the H3 receptor makes it significant in pharmacological research and potential therapeutic applications for cognitive disorders.

Option A: 4-methyl histamine is a non-selective histamine receptor agonist, primarily acting on H1 and H2 receptors, thus lacking the specificity required for selective H3 receptor activity.

Option B: Impromidine is an H2 receptor agonist, which does not target the H3 receptor, making it unsuitable for this question regarding selective H3 receptor agonists.

Option D: Mepyramine is an H1 receptor antagonist, which blocks rather than activates histamine receptors, failing to meet the criteria for a selective H3 receptor agonist.

Takeaways: Understanding the specificity of receptor agonists, such as the selective action of 2-Thiazolyl ethylamine on H3 receptors, is essential in pharmacology and requires knowledge of histamine receptor subtypes for effective therapeutic strategies.

Option A: A small particle aerosol generator is the most suitable device for administering ribavirin in aerosol form to infants with severe RSV. This device produces fine particles that can effectively deliver the medication to the lower respiratory tract, which is crucial for treating viral infections like RSV in young patients.

Option B: A small volume jet nebulizer produces larger aerosol particles that may not effectively reach the lower airways, making it less ideal for delivering ribavirin to infants with RSV.

Option C: A vibrating mesh nebulizer, while effective for many medications, may not be the best choice for ribavirin due to potential issues with drug delivery efficiency and particle size for this specific treatment.

Option D: A dry powder inhaler is not appropriate for infants, as it requires a certain level of inspiratory effort that infants typically cannot achieve, thus rendering it ineffective for this patient population.

Takeaways: Effective aerosol delivery of ribavirin for RSV in infants requires a small particle aerosol generator to ensure proper medication deposition in the lungs, as outlined in clinical guidelines for respiratory syncytial virus management.

Option A: Blocks of an endogenous bronchoconstrictor mediator. Ipratropium is an anticholinergic agent that works primarily by blocking muscarinic receptors in the airways, leading to bronchodilation and reduced bronchoconstriction. This mechanism is particularly beneficial in patients with COPD, as it helps alleviate airflow obstruction and improve respiratory function.

Option B: Inhibits cAMP breakdown via phosphodiesterase inhibition. This mechanism is characteristic of other classes of bronchodilators, such as methylxanthines, but does not apply to ipratropium, which does not act through phosphodiesterase inhibition.

Option C: Prevents antigen-antibody reactions that lead to mast cell mediator release. This describes the action of mast cell stabilizers or antihistamines, not ipratropium, which does not have a direct effect on mast cell stabilization or allergic reactions.

Option D: Stimulates ventilatory rates (CNS effect in brain's medulla). Ipratropium does not exert a central nervous system effect to stimulate ventilatory rates; its action is localized to the airways through peripheral mechanisms.

Takeaways: Understanding the mechanism of ipratropium as a blocker of an endogenous bronchoconstrictor mediator is crucial for managing COPD effectively, as it directly influences airway patency and patient comfort during exacerbations. For more information on this medication's role in respiratory therapy, see NIH's overview on anticholinergic medications.

Option A: Diuretic effect is not a recognized action of salbutamol. Salbutamol is a selective beta-2 adrenergic agonist primarily used for bronchodilation in asthma management. It does not exert a diuretic effect, which is typically associated with other classes of medications, such as thiazides or loop diuretics.

Option B: Positive inotropic effect refers to the increased force of heart muscle contraction, which can occur with beta-1 adrenergic stimulation. Salbutamol primarily targets beta-2 receptors, but it can have some beta-1 activity at higher doses, leading to a mild positive inotropic effect.

Option C: Skeletal muscle tremor is a recognized side effect of salbutamol due to its action on beta-2 receptors in skeletal muscle, which can lead to increased muscle excitability and tremors in some patients.

Option D: Smooth muscle relaxation is a primary action of salbutamol, as it works by stimulating beta-2 adrenergic receptors in the bronchial smooth muscle, leading to bronchodilation and relief of asthma symptoms.

Takeaways: Salbutamol is primarily known for its bronchodilatory effects and does not have a diuretic effect, which is a key distinction in pharmacology. Understanding the specific actions of medications like salbutamol is essential for effective asthma management and patient education, including recognizing potential side effects.